PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis

Po Lin So, Grace Y. Wang, Kevin Wang, Mindy Chuang, Venice Calinisan Chiueh, Paraic A. Kenny, Ervin H. Epstein

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Basal cell carcinoma (BCC) is the most common human cancer. We have demonstrated previously that topical application of the retinoid prodrug tazarotene profoundly inhibits murine BCC carcinogenesis via retinoic acid receptor γ-mediated regulation of tumor cell transcription. Because topical retinoids can cause adverse cutaneous effects and because tumors can develop resistance to retinoids, we have investigated mechanisms downstream of tazarotene's antitumor effect in this model. Specifically we have used (i) global expression profiling to identify and (ii) functional cell-based assays to validate the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway as a downstream target pathway of tazarotene's action. Crucially, we have demonstrated that pharmacologic inhibition of this downstream pathway profoundly reduces murine BCC cell proliferation and tumorigenesis both in vitro and in vivo. These data identify PI3K/AKT/mTOR signaling as a highly attractive target for BCC chemoprevention and indicate more generally that this pathway may be, in some contexts, an important mediator of retinoid anticancer effects.

Original languageEnglish (US)
Pages (from-to)407-417
Number of pages11
JournalCancer Prevention Research
Volume7
Issue number4
DOIs
StatePublished - 2014

Fingerprint

1-Phosphatidylinositol 4-Kinase
Basal Cell Carcinoma
Retinoids
Carcinogenesis
Neoplasms
Retinoic Acid Receptors
Chemoprevention
Prodrugs
Cell Proliferation
Skin
tazarotene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

So, P. L., Wang, G. Y., Wang, K., Chuang, M., Chiueh, V. C., Kenny, P. A., & Epstein, E. H. (2014). PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. Cancer Prevention Research, 7(4), 407-417. https://doi.org/10.1158/1940-6207.CAPR-13-0304

PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. / So, Po Lin; Wang, Grace Y.; Wang, Kevin; Chuang, Mindy; Chiueh, Venice Calinisan; Kenny, Paraic A.; Epstein, Ervin H.

In: Cancer Prevention Research, Vol. 7, No. 4, 2014, p. 407-417.

Research output: Contribution to journalArticle

So, Po Lin ; Wang, Grace Y. ; Wang, Kevin ; Chuang, Mindy ; Chiueh, Venice Calinisan ; Kenny, Paraic A. ; Epstein, Ervin H. / PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. In: Cancer Prevention Research. 2014 ; Vol. 7, No. 4. pp. 407-417.
@article{c0b2475493d84c28b7d478db08c3e92f,
title = "PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis",
abstract = "Basal cell carcinoma (BCC) is the most common human cancer. We have demonstrated previously that topical application of the retinoid prodrug tazarotene profoundly inhibits murine BCC carcinogenesis via retinoic acid receptor γ-mediated regulation of tumor cell transcription. Because topical retinoids can cause adverse cutaneous effects and because tumors can develop resistance to retinoids, we have investigated mechanisms downstream of tazarotene's antitumor effect in this model. Specifically we have used (i) global expression profiling to identify and (ii) functional cell-based assays to validate the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway as a downstream target pathway of tazarotene's action. Crucially, we have demonstrated that pharmacologic inhibition of this downstream pathway profoundly reduces murine BCC cell proliferation and tumorigenesis both in vitro and in vivo. These data identify PI3K/AKT/mTOR signaling as a highly attractive target for BCC chemoprevention and indicate more generally that this pathway may be, in some contexts, an important mediator of retinoid anticancer effects.",
author = "So, {Po Lin} and Wang, {Grace Y.} and Kevin Wang and Mindy Chuang and Chiueh, {Venice Calinisan} and Kenny, {Paraic A.} and Epstein, {Ervin H.}",
year = "2014",
doi = "10.1158/1940-6207.CAPR-13-0304",
language = "English (US)",
volume = "7",
pages = "407--417",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis

AU - So, Po Lin

AU - Wang, Grace Y.

AU - Wang, Kevin

AU - Chuang, Mindy

AU - Chiueh, Venice Calinisan

AU - Kenny, Paraic A.

AU - Epstein, Ervin H.

PY - 2014

Y1 - 2014

N2 - Basal cell carcinoma (BCC) is the most common human cancer. We have demonstrated previously that topical application of the retinoid prodrug tazarotene profoundly inhibits murine BCC carcinogenesis via retinoic acid receptor γ-mediated regulation of tumor cell transcription. Because topical retinoids can cause adverse cutaneous effects and because tumors can develop resistance to retinoids, we have investigated mechanisms downstream of tazarotene's antitumor effect in this model. Specifically we have used (i) global expression profiling to identify and (ii) functional cell-based assays to validate the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway as a downstream target pathway of tazarotene's action. Crucially, we have demonstrated that pharmacologic inhibition of this downstream pathway profoundly reduces murine BCC cell proliferation and tumorigenesis both in vitro and in vivo. These data identify PI3K/AKT/mTOR signaling as a highly attractive target for BCC chemoprevention and indicate more generally that this pathway may be, in some contexts, an important mediator of retinoid anticancer effects.

AB - Basal cell carcinoma (BCC) is the most common human cancer. We have demonstrated previously that topical application of the retinoid prodrug tazarotene profoundly inhibits murine BCC carcinogenesis via retinoic acid receptor γ-mediated regulation of tumor cell transcription. Because topical retinoids can cause adverse cutaneous effects and because tumors can develop resistance to retinoids, we have investigated mechanisms downstream of tazarotene's antitumor effect in this model. Specifically we have used (i) global expression profiling to identify and (ii) functional cell-based assays to validate the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway as a downstream target pathway of tazarotene's action. Crucially, we have demonstrated that pharmacologic inhibition of this downstream pathway profoundly reduces murine BCC cell proliferation and tumorigenesis both in vitro and in vivo. These data identify PI3K/AKT/mTOR signaling as a highly attractive target for BCC chemoprevention and indicate more generally that this pathway may be, in some contexts, an important mediator of retinoid anticancer effects.

UR - http://www.scopus.com/inward/record.url?scp=84898841252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898841252&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-13-0304

DO - 10.1158/1940-6207.CAPR-13-0304

M3 - Article

VL - 7

SP - 407

EP - 417

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 4

ER -